Refine your search

Search Results within category "Neurology"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Neurology"


3 Study Matches

Characterization of Agrin/LRP4 Antibody Positive Myasthenia Gravis

This study will evaluate new autoantibodies that might explain symptoms in patients with double negative myasthenia gravis (DNMG). If these newly identified autoantibodies are associated with different subtypes of MG, being able to test for them will allow clinicians to have a biomarker that will identify patients with these subsets of MG.
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with myasthenia gravis AND negative for myasthenia gravis-related antibodies OR
Diagnosed with another neuromuscular disorder that is not myasthenia gravis OR
Not diagnosed with any neuromuscular disorder
At least 21 years old
Exclusion Criteria:
Received IVIG treatments within the last 6 weeks
Received plasma exchange withing the last 6 weeks
Received treatment with rituximab within the last 24 weeks
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

The primary purpose of this phase 3 clinical trial is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03920293
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with myasthenia gravis for at least 6 months
Myasthenia Gravis Foundation of America (MGFA) classification: Class II to IV
Weigh at least 40 kg (about 88 lbs)
Exclusion Criteria:
History of thymectomy (removal of the thymus gland) within 12 months
Active or untreated thymoma (tumor of the thymus gland)
History of meningococcal infection
HIV infection
Pregnancy
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

The purpose of this study is to learn about the safety and effectiveness of amifampridine phosphate in people with myasthania gravis (MG).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03304054
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of MG as Class II to Class IV
positive serologic test for anti-MuSK antibodies or anti-AChR antibodies
Exclusion Criteria:
Have epilepsy
Have a long QT syndrome
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA